Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Top Cited Papers
- 20 September 2009
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 374 (9699), 1432-1440
- https://doi.org/10.1016/s0140-6736(09)61497-5
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III StudiesThe Oncologist, 2009
- Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51)Lung Cancer, 2007
- Optimizing First-Line Treatment Options for Patients with Advanced NSCLCThe Oncologist, 2005
- ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC)Annals of Oncology, 2005
- Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2005
- Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non–Small-Cell Lung Cancer CellsMolecular Pharmacology, 2005
- Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancerLung Cancer, 2005
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scaleCancer, 1994